Compare GSK plc (GSK) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vital Farms Inc — how do they compare? GSK plc trades at $52.66 (market cap $101.34B), while Vital Farms Inc trades at $13.4 (market cap $581.88M). The key difference: GSK plc is far larger — about 174.2× Vital Farms Inc's market cap, and GSK plc pays a 3.49% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| GSK | VITL | |
|---|---|---|
Market Cap | $101.34B | $581.88M |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $52.41 |
52-Week Low | $36.20 | $8.28 |
Enterprise Value | $121.95B | $584.69M |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Vital Farms (VITL) trades at $13.54, up 3.28% with a bullish technical signal from moving averages and oscillators. The company shows solid fundamentals with a P/E of 13.06, P/S of 0.79, and strong profitability margins (ROE 15.44%, net margin 6.1%). Recent earnings have been mixed with Q3 2025 beating expectations but Q1 2026 missing, while analyst consensus remains positive with 56% buy ratings and a $13.50 price target.
The outlook suggests potential upside to the $16 high target given reasonable valuation and profitability, but risks include ongoing class action lawsuits, negative cash flow trends, and earnings volatility. Revenue growth is projected to slow from 2025 to 2026 with profit margins compressing from 8.72% to 6.1%, indicating execution challenges ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
